The DOI matches its Crossref record; 305 of the 305 references it cites were found in a registry or an index.
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document
Abstract
Many important decisions on hypertension management must currently be taken without the support of evidence \nfrom large randomized controlled trials. The following issues appear in urgent need to be approached by simply \ndesigned trials. \n(1) Should antihypertensive drugs be prescribed to all patients with grade 1 hypertension, even when total \ncardiovascular risk is relatively low or moderate? Because of the very low rate of cardiovascular events \nexpected in these patients, a placebo-controlled trial using intermediate endpoints such as signs of organ \ndamage of recognized prognostic importance would be feasible, ethical, and clinically relevant. \n(2) Should antihypertensive drugs be prescribed to the elderly with grade 1 hypertension, and should antihypertensive \ntreatment achieve a goal of below 140/90mmHg also in the elderly? These trials could make use \nof hard cardiovascular outcomes and could be placebo-controlled. \n(3) Should antihypertensive drug treatment be started in diabetic patients or in patients with previous cerebrovascular \nor cardiovascular disease when BP is still in the high normal level, and should BP goal be below 130/ \n80mmHg in these patients? These issues can be approached by placebo-controlled trials because no trial \nevidence is still available on the benefit of lowering high normal BP or of achieving BP goals below 130/ \n80mmHg. \n(4) What are the lowest safe BP values to achieve by treatment in different clinical conditions? This issue should \nbe approached by trials comparing more or less intense BP-lowering treatment strategies in patients with \ndifferent cardiovascular risk levels. \n(5) Are lifestyle measures known to reduce BP also capable of reducing morbidity and mortality in hypertension? \nA controlled randomized trial using intermediate endpoints (organ damage) would be feasible and desirable \nin patients with high normal BP or grade 1 hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Nakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T., & Ideura, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12229-5 · Cited by 970
RetractedChobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Global burden of hypertension: analysis of worldwide data
Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., & He, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17741-1 · Cited by 8,594
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Self-citationTurner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Self-citationOlmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
Haller, H., Ito, S., Izzo, J. L., Januszewicz, A., Katayama, S., Menne, J., Mimran, A., Rabelink, T. J., Ritz, E., Ruilope, L. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007994 · Cited by 792
Self-citationCooper-DeHoff, R. M., Gong, Y., Handberg, E. M., Bavry, A. A., Denardo, S. J., Bakris, G. L., & Pepine, C. J. (2010) · JAMA · doi:10.1001/jama.2010.884 · Cited by 651
Impact of diabetes on cardiovascular disease: an update
Matheus, A. S. D. M., Tannus, L. R. M., Cobas, R. A., Palma, C. C. S., Negrato, C. A., & Gomes, M. D. B. (2013) · International Journal of Hypertension · doi:10.1155/2013/653789 · Cited by 547
Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Blood Pressure · doi:10.3109/08037051.2013.812549 · Cited by 426
Self-citation
Metadata
- Authors
- Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M. J., Cifkova, R., Clément, D., Coca, A., Dominiczak, A., Erdine, S., Fagard, R., Farsang, C., Grassi, G., Haller, H., Heagerty, A., Kjeldsen, S. E., Kiowski, W., Mallion, J. M., Manolis, A., Narkiewicz, K., Nilsson, P., Olsen, M. H., Rahn, K. H., Redon, J., Rodicio, J., Ruilope, L., Schmieder, R. E., Struijker-Boudier, H. A. J., Van Zwieten, P. A., Viigimaa, M., & Zanchetti, A.
- Venue
- Blood Pressure
- Publisher
- Informa UK Limited
- Published
- 2009-01
- Volume
- 18
- Issue
- 6
- Pages
- 308-347
- ISSN
- 0803-7051 (ISSN-L)
- 1651-1999
- OpenAlex
- W1988716175
- Cited by
- 894
- References
- 305
- FWCI
- 88.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. https://app.cochat.ai/papers/10.3109/08037050903450468
- The paper
- Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M. J., Cifkova, R., Clément, D., Coca, A., Dominiczak, A., Erdine, S., Fagard, R., Farsang, C., Grassi, G., Haller, H., Heagerty, A., Kjeldsen, S. E., Kiowski, W., Mallion, J. M., . . . Zanchetti, A. (2009). Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure. https://doi.org/10.3109/08037050903450468
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
